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Background
Although whole-genome association studies have detected 
dozens of common variants for a broad range of complex 
diseases, and are likely to detect many more, the total 
variance  explained  by  the  known  variants  is  typically 
modest  [1,2].  As  such,  realising  the  goals  of  accurate 
genetic risk prediction and the subsequent opportunities 
of personalised medicine remains difficult [3,4]. Indeed, 
it  has  often  been  noted  that  family  history  alone  will 
perform  substantially  better  as  a  predictor  of  risk, 
compared to genotype data for known risk variants [5]. It 
is true that a positive family history will likely remain an 
important  factor  in  prediction  for  the  many  complex 
diseases with substantial heritabilties and shared familial 
environmental  components.  (A  caveat  is  that  family 
history  information  might  sometimes  not  be  straight-
forwardly available - for example, for phenotypes such as 
response to a particular drug treatment.) However, analo-
gous to clinical genetic testing for Mendelian disease, it is 
plausible that in many cases a positive family history will 
itself be a motivating factor for pursuing a genetic test. 
For example, an individual whose older sibling developed 
a particular disease might be particularly concerned with 
their own personal risk, which they assume will be higher 
than average. In this context, in which a genetic test is 
sought  because  a  first-degree  relative  has  disease,  we 
developed a family-based model for risk prediction incor-
porating genotype data from both the index individual and 
a relative of known phenotype. As such, we do not ask 
‘how  well  do  single  nucleotide  polymorphisms  predict 
disease compared to family history’ , but rather, ‘how well 
do  single  nucleotide  polymorphisms  predict  disease 
given a positive family history, and to what extent does 
including genotype data from the affected relatives help?’
Information from relatives of known phenotype
For  diseases  with  polygenic  and  shared  environmental 
components of risk, the genotype of a relative of known 
phenotype can be informative for an individual’s disease 
risk, over and above the individual’s own genotype at that 
locus. Below, the term genotype here refers to both single 
and multi-locus genotypes, unless explicitly stated. We 
assume  that  genotypes  at  the  locus  or  loci  under 
considera  tion only account for a proportion of the total 
familial  covariance,  meaning  that  unmeasured  residual 
polygenic and/or shared environmental factors still exist, 
as would be expected for a complex disease.
Ignoring the relative’s phenotype, then as expected, in 
an unselected population a relative’s genotype does not 
predict  the  index  individual’s  disease  risk  given  the 
index’s  own  genotype.  That  is,  if  index  disease  DI  is 
modeled  as  a  function  of  index  genotype  GI  and,  for 
example, sibling genotype GS:
logit(DI) = b0 + b1GI + b2GS + e
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phenotype of the sibling, DS, and include it in the model:
logit(DI) = b0 + b1GI + b2GS + b3DS + e
then if E(b1) > 0, for example, E(b2) will no longer equal 
zero.  In  fact,  in  this  case,  E(b2)  <  0,  meaning  that  the 
sibling’s genotype is informative for the index’s disease 
risk, in the opposite direction compared to b1.
Why is the sibling genotype conditional on index geno-
type and sibling phenotype informative for index disease 
risk? For a given risk locus, if the sibling is affected but 
has a low-risk genotype, this implies that the index is at 
higher  risk  than  if  the  affected  sibling  has  a  high-risk 
genotype,  conditional  on  the  index’s  own  genotype  at 
that locus. In this scenario, the affected sibling’s genotype 
acts as a surrogate for all other unmeasured risk factors: 
if the sibling has the low-risk genotype but still is affected, 
he  or  she  is  likely  to  have  a  higher  rate  of  other, 
unobserved risk factors, either genetic or environmental. 
To  the  extent  that  these  unobserved  risk  factors  are 
shared among siblings, the affected sibling’s genotype will 
therefore act as a surrogate for the index’s unobserved 
risks. This is analogous to the epidemiological pheno  me-
non of selection bias, in which an association arises due 
to shared but unmeasured factors.
In general, a lower genetic load of known risk variants in 
an affected relative will tend to increase the index’s risk of 
disease, over and above the level of risk predicted by the 
index’s own genotype. For the index, a higher genetic load 
still leads, as usual, to a higher predicted risk. (Note that if 
we did not know the index genotype, the affected relative’s 
genotype would act as a surrogate for it. In this case, a 
higher load of known risk variants in the affected relative 
would predict a higher, not lower, risk in the index. Unless 
the  affected  relative  is  a  monozygotic  twin,  prediction 
would naturally be worse than if we knew the actual index 
genotype.) In the rest of this report, we applied this obser-
vation to the problem of genetic risk prediction, asking 
whether  the  inclusion  of  genotypes  from  a  relative  of 
known phenotype can improve the accuracy of prediction.
Methods
Prediction model incorporating family information
Here we introduce a model in which the relative of known 
phenotype is an affected sibling; the basic approach can be 
easily  extended  to  other  and  multiple  relative  types. 
Specifically, we wish to predict disease risk for the index 
individual, conditional on: their multilocus genotype at V 
known  disease  variants;  their  affected  sibling’s  disease 
state;  and  additionally  including  the  affected  sibling’s 
multilocus genotype.
For two siblings (with subscripts I and S for the index 
and affected sibling, respectively), we model disease state 
D given genotypes G at one or more loci. Estimates of 
population allele frequencies and relative risks for G are 
assumed to be known in advance. The probability that 
the  index  develops  disease  given  both  their  and  their 
affected sibling’s genotype at a single locus is:
                                P(DI,DS|GI,GS)
P(DI|GI,GS,DS) = ____________________________
                                   P(DS|GI,GS)
where P(DI,DS|GI,GS) and P(DS|GI,GS) = ∑DIP(DI,DS|GI,GS) 
are  directly  obtained  from  the  multivariate  normal 
cumulative  distribution  function,  assuming  a  liability-
threshold model for disease risk.
The liability-threshold model assumes an unobserved, 
normally-distributed liability (Q); individuals with liability 
values above a threshold are affected. For threshold t:
P(Q ≥ t) = k
where k is the specified population prevalence of disease. 
For two family members, the probability of joint sibling 
disease state D given genotypes G is:
P(DI,DS|GI,GS) = P(QI ≥ t, QS ≥ t)
and the joint cumulative distribution of Q is given by the 
multivariate normal distribution function:
                              μI|GI                   σA
2 + σC
2 + σE
2       σA
2/2+ σC
2 
QI,QS → N ([
         ]
 , [
                                                 ])                               μS|GS                  σA
2/2+ σC
2                 σA
2 + σC
2 + σE
2
The expected value of Q is a function of the genotypes 
for  each  sibling,  GI  and  GS;  the  residual  variance  is 
partitioned into the components of variance representing 
polygenes (σA
2), family-wide common environmental factors 
(σC
2) and individual-specific, or nonshared, factors, includ-
ing measurement error (σE
2). These variance components 
must be specified in advance - for example, from twin 
and family studies.
For a given individual, we use the likelihood ratio as a 
measure of risk of being affected, DI, versus unaffected, D –
I 
[6], extended here to incorporate genotypic and pheno-
typic information on the sibling, GS and DS:
            P(GI,GS,DS|DI)
L = _______________________
           P(GI,GS,DS|D –
I)
where:
                                   P(DI|GI,GS,DS)P(GI,GS,DS)
P(GI,GS,DS|DI) = ___________________________________________
                                 ∑GIP(DI|GI,GS,DS)P(GI,GS,DS)
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P(GI,GS,DS) = P(GI,GS|DS)P(DS)
The  population  joint  sibship  genotype  frequencies 
P(GI,GS)  are  calculated  assuming  random  mating  and 
Hardy-Weinberg equilibrium in the population, summing 
over all possible parental mating and transmission types. 
Conditioning on proband disease state, then:
                                P(DS|GI,GS)P(GI,GS)
P(GI,GS|DS) = _______________________________________
                             ∑GI ,GSP(DS|GI,GS)P(GI,GS)
These  likelihoods  can  be  combined  across  multiple 
independent loci, as log(LM) = ∑vlog(Lv) where Lv is the 
likelihood ratio for variant v. Then, following Yang et al. 
[6], the risk of disease for the index is given by:
                                                 LMP(DI|DS)
P(DI|GI,GS,DS) = __________________________________________
                                  1 – P(DI|DS) + LMP(DI|DS)
Simulation study of Crohn’s disease variants
We  simulated  data  to  approximate  the  set  of  30  risk 
variants reported in Barrett et al. [8] as follows. We set 
the disease prevalence to k = 1/250. (In practice, deter-
mination of affection status was based on fixed threshold 
on the normal liability scale, and so the implied preva-
lence  will  vary  slightly  around  1/250  when  non-null 
genetic effects are specified. This effect is very small and 
does  not  impact  the  comparisons  of  methods  and 
conclusions,  however.)  The  risk  allele  frequency  (RAF) 
and  genotypic  relative  risk  (GRR)  for  each  variant  are 
reported  in  Table  1.  Given  k,  RAF  and  GRR  for  each 
variant, we estimated the implied additive genetic value a 
by numerical optimization.
In all cases, we set the polygenic variance components 
σA
2 = 0.7, σC
2 = 0.2 and σE
2 = 0.1, which implies a risk to 
individuals with at least one affected sibling of 0.11 and, 
therefore, a sibling relative risk of 28.6 [7]. Note that the 
performance of the family model depends on the residual 
sibling correlation:
  σA
2 /2 + σC
2
___________________
σA
2 + σC
2 + σE
2
and not just the individual values of values of σA
2 and σC
2 
(that is, all pairs of values that yield the same implied 
sibling correlation will show identical performance).
For  the  unselected  population  we  simulated  500,000 
nuclear  families,  each  with  two  siblings.  For  the 
family-history positive population, we simulated 100,000. 
Fewer replicates were required due to the much higher 
baseline rate for DI in this population.
Results and discussion
Single locus example
To illustrate the approach, we analytically calculated the 
expected  risk  under  a  variety  of  models,  based  on 
information from a single locus - rs2188962 - one of the 
Crohn’s disease loci identified in a recent meta-analysis 
[8],  setting  the  GRR  to  1.25  and  the  RAF  to  0.425. 
Prevalence, additive polygenic and shared environmental 
Table 1. Crohn’s disease model specification
RAF  GRR  a  VE
0.018  3.99  0.504  .0090
0.533  1.28  0.098  .0048
0.425  1.25  0.083  .0034
0.899  1.31  0.135  .0033
0.387  1.25  0.083  .0032
0.152  1.35  0.106  .0029
0.677  1.22  0.080  .0028
0.463  1.21  0.071  .0025
0.478  1.20  0.067  .0023
0.678  1.20  0.072  .0022
0.780  1.21  0.079  .0022
0.221  1.25  0.079  .0022
0.933  2.50  0.130  .0021
0.125  1.32  0.097  .0021
0.565  1.18  0.062  .0019
0.565  1.18  0.062  .0019
0.697  1.18  0.064  .0017
0.271  1.20  0.065  .0016
0.090  1.33  0.099  .0016
0.243  1.19  0.061  .0014
0.386  1.16  0.053  .0013
0.289  1.17  0.055  .0013
0.345  1.16  0.053  .0013
0.682  1.14  0.049  .0010
0.389  1.13  0.043  .0009
0.473  1.12  0.040  .0008
0.348  1.12  0.040  .0007
0.017  1.54  0.149  .0007
0.708  1.11  0.038  .0006
0.619  1.08  0.027  .0004
Values used to generate simulated Crohn’s disease samples. RAF, risk allele 
frequency; GRR, genotypic relative risk, estimated from the reported odds ratios; 
a, additive genetic value; VE, variance explained.
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values for Crohn’s disease, as described above. Figure 1 
shows the predicted disease risks under five models: no 
information, P(DI); conditional on index genotype, P(DI|GI); 
conditional  on  having  an  affected  sibling  status  alone, 
P(DI|DS); as above, including index genotype, P(DI|GI,DS); 
as above, including sibling genotype, P(DI|GI,GS,DS).
Conditional  on  index  genotype,  the  affected  sibling’s 
genotype  further  stratifies  risk,  but  with  the  low-risk 
genotype predicting increased risk for the index. Values 
of P(DI|GI) only range around P(DI), from 0.32% to 0.52% 
for  the  low-risk  to  high-risk  homozygotes,  whereas 
P(DI|GI,GS,DS)  shows  a  much  greater  range  around 
P(DI|DS), from 8.9% to 14.6%. The predicted risks shown 
here  were  reproduced  by  simulating  data  under  this 
model and calculating the proportion of index cases for 
each configuration (data not shown).
Figure  2  illustrates  the  relative  performance  of  the 
different models under varying levels of effect size and 
background  residual  familial  variance.  In  general,  the 
absolute  and  relative  impact  of  the  affected  sibling’s 
genotype increases with both of these factors.
Crohn’s disease simulation
We next performed a simulation as described above that 
included  all  30  Crohn’s  disease  variants  reported  in 
Barrett et al. [8], which collectively account for 6.4% of 
the  total  variance  (calculated  assuming  a  liability-
threshold model and assuming additivity across loci on 
the  scale  of  liability).  We  first  simulated  a  simple 
unascertained sample of nuclear families, each with two 
siblings  (that  is,  DS  will  only  be  affected  at  the  usual 
population  prevalence).  Second,  we  used  rejection 
sampling to simulate an ascertained sample in which at 
least one sibling was affected (DS is always affected). For 
each simulated family, we calculated the risk for the index 
being affected, DI, using the methods described above.
We  evaluated  performance  using  three  metrics:  the 
area under the receiver operating characteristic (ROC) 
curve  (AUC);  the  squared  correlation  between  true 
Figure 1. Predicted index disease risk. Predicted index disease risks from a single locus (minor allele frequency = 0.425, GRR = 1.25): 
unconditonal, P(DI); conditional on index genotype, P(DI|GI); conditional on affected sibling phenotype, P(DI|DS); conditional on index genotype and 
affected sibling phenotype, P(DI|GI,DS); conditional on index and sibling genotypes and affected sibling phenotype, P(DI|GI,GS,DS). The inserted table 
contains frequencies of sibling pair genotype combinations conditional on at least one sibling being affected. Red represents the homozygous risk-
increasing genotype; green the heterozygous genotype; blue the homozygous risk-decreasing genotype.
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Page 4 of 7disease state and predicted risk (R2); and the enrichment 
in the rate of cases versus the population prevalence for 
individuals in the highest 1, 5, or 10% of estimated risk 
(T1,  T5  and  T10).  We  assessed  performance  for  three 
models:  P(DI|GI),  P(DI|GI,DS)  and  P(DI|GI,GS,DS).  All 
results are shown in Table 2.
We first describe results for the general population, in 
which  nuclear  families  were  generated  without  any 
ascertainment on disease. As expected, compared to the 
basic model P(DI|GI), the inclusion of a sibling phenotype 
DS  (which  might  be  affected  or  unaffected)  improved 
both risk prediction for the index, particularly as indexed 
by R2 (0.054 to 0.085). The enrichment of cases in the 
highest-ranked 1% (T1) more than doubled (7.39 to 15.9). 
In this population, however the addition of the sibling’s 
genotypes  GS  added  only  marginal  benefit  in  terms  of 
AUC and R2, and no benefit for the T metrics.
In the second population, we ascertained for a positive 
family  history  (that  is,  DS  is  always  affected).  Of  note, 
compared to the unselected population, the AUC and R2 
metrics  are  considerably  lower  in  this  high-risk  popu-
lation,  whereas  the  T  metrics  are  substantially  higher 
(largely  reflecting  the  high  sibling  relative  risk  for  this 
disease). That the discriminative performance of a test 
may vary depending on the characteristics of the popu-
lation it is deployed in may have important implications 
for  the  generalizability  of  studies  that  claim  a  certain 
AUC, which is not an invariant property of the test alone 
but depends on the context in which it is used.
In terms of discrimination, the basic P(DI|GI) model as 
expected  yields  near  identical  results  compared  to 
P(DI|GI,DS), as all siblings are affected in this population; 
we therefore omit this model here. However, the absolute 
values of predicted risk based on P(DI|GI) will be very 
poorly calibrated, as this model ignores the presence of a 
positive family history. For example, for individuals with 
a predicted risk of 0.1 ± 0.01 from the P(DI|GI,DS) model, 
we observed a rate of 0.099 cases in the simulated data. 
Figure 2. Predicted index disease risks from a single locus, under a variety of genetic models. Predicted index disease risk stratified by 
(a) effect size and (b) total sibling relative risk. See Figure 1 legend for details. In all cases, risk allele frequency is 0.425, disease prevalence is 1/250. 
(a) Varying the familial variance component of the residual variance from 20%, 50% to 80%, with corresponding sibling relative risks of 3.25, 12.25 
and 35.5. (b) Varying additive genetic effect from a = 0.01, a = 0.05 to a = 0.1, with corresponding genotypic relative risks of 1.03, 1.16 and 1.30.
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Page 5 of 7However, based on P(DI|GI), these same individuals had a 
mean predicted risk of only 0.0037. In other words, by 
not  conditioning  on  known  affected  sibling  status,  the 
prediction  model  will  dramatically  underestimate  the 
absolute risks.
Finally, we considered whether adding sibling geno  types 
improved  prediction  in  this  family-history  positive 
population. We observed negligible improvement in AUC 
(1.03-fold increase) but a larger increase for R2 (1.33-fold, 
0.042 to 0.056). There were also increases in the already-
large  T  metrics.  As  expected,  the  benefit  derived  from 
including  sibling  genotypes  is  larger  in  the  ascertained 
population because, for a relatively rare but highly familial 
disease,  affected  siblings  will  be  more  informative  than 
unaffected  siblings.  In  the  family-history  positive 
population, adding affected sibling geno  types offers some 
advantage,  although  likely  not  enough  to  ever 
fundamentally change the discriminative utility of a test.
Including affected sibling genotypes can improve the 
calibration  of  predicted  risks  somewhat  and  lead  to  a 
greater stratification of risk, as apparent in Figure 1. We 
can quantify the risk stratification depicted in Figure 1 in 
terms  of  a  metric  δ.  Comparing  two  sets  of  predicted 
risks, we define δ as the expected change in risk, calcu-
lated as ∑i|Pi – Qi/|N of N total individuals, where Pi is 
the probability of disease in the individual before the test 
and Qi is the probability afterwards. This is one way of 
characterizing the personal impact of a test: the expected 
change  in  estimated  risk  pre-  versus  post-test.  In  the 
family-history  positive  population,  δ  for  P(DI|GI,DS)  is 
0.035; the incremental δ going from the risks estimated 
based on P(DI|GI,DS) to P(DI|GI,GS,DS) is 0.02. In other 
words, updating one’s risk based on an affected sibling’s 
genotype would be expected to change one’s predicted 
risk 57% (0.02/0.035) as much as the initial test (in the 
unselected population, this value is 50%).
Including additional and/or unaffected family members
We also considered models in which additional affected 
family members are included in the model: for example, 
individuals in multiplex families with an affected sibling 
and  an  affected  parent,  or  two  affected  siblings.  In 
general, we do see improvement from incorporating the 
genotypes of these additional affected relatives, although 
there tends to be a diminishing return (data not shown).
In practice, for most diseases, being of relatively low 
frequency (for example, under 10%), only affected rela-
tives will contribute information, compared to rela  tives 
known to be disease-free. In addition, determination that 
an individual is disease-free with respect to life-time risk 
might be difficult.
Limitations
One caveat is that if the known variants used in the test 
themselves  account  for  the  entire  familial  covariance, 
then  genotypes  from  phenotyped  relatives  will  not 
contribute any additional information. This is unlikely to 
be the case in the foreseeable future for most diseases, 
however; it would imply that we have already maximized 
the potential of genetic risk prediction.
For this work we have assumed a particular model for 
risk, additivity on the scale of liability, which in practice 
approximates a multiplicative model on the scale of risk. 
This implies that the same risk ratio will correspond to a 
larger absolute risk difference if there is a higher baseline 
risk: for example, 1% versus 2% and 5% versus 10% both 
imply  risk  ratios  of  2,  but  varying  absolute  risk  differ-
ences. This effect is evident in Figure 1, in which genotype 
leads  to  a  greater  stratification  of  absolute  risk  in 
individuals with an affected sibling. Whether or not the 
implied penetrances for individuals with a positive family 
history  actually  follow  this  model  is  a  question  that 
ultimately  should  be  empirically  addressed,  to  indicate 
the adequacy of the risk model. However, this does not 
alter the qualitative principle outlined here that relatives’ 
genotypes  and  phenotypes  are  informative  for  an 
individual’s disease risk.
Conclusions
We  observed  that  the  genotypes  of  relatives  of  known 
pheno  type  are  informative  for  an  individual’s  risk, 
independent of the same risk variants measured in the 
index individual. We sought to determine whether this 
phenomenon could be of use in the context of genetic 
disease  risk  prediction.  We  described  and  evaluated  a 
prediction  model  for  individuals  with  one  or  more 
affected  first-degree  relatives.  Our  model  has  the  key 
feature  of  incorporating  genotype  information  from 
relatives to improve the accuracy of prediction. The basic 
insight - that affected relatives’ genotypes are informative 
about an individual’s risk for a multifactorial, polygenic 
Table 2. Crohn’s disease simulation results
Model  AUC  R2  T1  T5  T10
General population
  P(DI|GI)  0.708  0.054  7.39  4.21  3.23
  P(DI|GI,DS)  0.726  0.085  15.90  5.71  3.91
  P(DI|GI,GS,DS)  0.735  0.094  15.88  5.80  3.94
Selected population (affected sibling)
  P(DI|GI,DS)  0.628  0.042  71.25  60.25  53.75
  P(DI|GI,GS,DS)  0.648  0.056  82.00  67.20  58.48
Performance characteristics for tests based on the 30 Crohn’s disease variants. 
Index individuals and their siblings were simulated in the unselected and 
selected (family history positive/affected sibling) scenarios. The prediction 
models estimate risk based on the index genotype GI, and optionally sibling’s 
phenotype DS and genotype GS. The metrics are the area under the ROC curve 
(AUC), the squared correlation between disease state and risk (R2) and the 
relative enrichment of cases in the top 1, 5 and 10% of individuals with the 
highest risk scores relative to the baseline risk for that population (T1, T5 and T10). 
See main text for details.
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approach presented here and could be used with other 
prediction methodologies. In this work, we focused on 
the additive effects of confirmed disease alleles, although 
others have incorporated other sources of information, 
including  non-genetic  risk  factors  [9]  and  interactions 
between  risk  factors  [6].  To  the  extent  that  such  risk 
factors  are  shared  between  relatives,  the  approach 
outlined  here  to  include  information  from  affected 
relatives could also be applied in these other contexts. 
Methodologically,  we  used  a  liability  threshold  model. 
Others have developed prediction models using logistic 
regression  [6],  optimal  ROC  curves  [10],  Bayesian 
networks [11] and support vector machines [12], using 
diverse criteria to evaluate performance in terms of, for 
example, discrimination, calibration and reclassification 
[13]. Again, information from affected relatives could in 
theory be included using any of these approaches. In fact, 
our  approach  is  conceptually  similar  to  methods  in 
livestock genetics and animal breeding that use genetic 
marker data for prediction, using all the data and taking 
into account familial relationships in complex pedigrees 
[14].  However,  in  the  context  of  human  disease  risk 
prediction, our simulations suggest that, in most cases, 
only  incremental  improvements  are  to  be  expected, 
meaning it is unlikely that the overall applicability of a 
test will be fundamentally altered.
Abbreviations
AUC, area under the curve; GRR, genotypic relative risk; RAF, risk allele 
frequency; ROC, receiver operating characteristic.
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